Thirumalai Chemicals Limited sees a credit rating action
TL;DR
ICRA’s latest rationale highlights the company's reliance on short-term debt for working capital; what is the current utilization level of the fund-based working capital limits, and how does this compare to the peak utilization observed in the last four quarters?
The current utilization percentage cannot be confirmed from the cited ICRA update. ICRA reports the fund-based working-capital limit at ₹334.5 Cr, unchanged from the previous rating action, but does not provide the amount drawn or the utilization percentage.[1]
The company’s current borrowings were ₹586.06 Cr in Q2 FY27, but this is total current borrowings and cannot be treated as utilization of the ₹334.5 Cr working-capital facility.[2]
Accordingly, the peak utilization over the last four quarters—Q3 FY26 to Q2 FY27—could not be confirmed from the cited sources. A valid comparison requires quarter-end drawings specifically against the fund-based working-capital limits, not total current borrowings.
The rating rationale cites ongoing capital expenditure at the Dahej facility; what is the total debt-funded portion of this specific project, and how does the current debt-to-equity ratio align with the covenants or thresholds specified by the lenders in the latest credit facilities?
The debt-funded portion of the Dahej project cannot be confirmed from the latest cited materials. In fact, the latest project reference identifies ongoing capex at TCL Specialties LLC’s US greenfield facility, not Dahej [3]. No project-level cost or debt/equity funding split is reported there.
Current leverage
As of Q2 FY27, consolidated total debt was ₹2,142.0 Cr and total equity was ₹1,523.1 Cr [4] [5].
- Gross debt-to-equity = 1.41x, derived as ₹2,142.0 Cr / ₹1,523.1 Cr.
- On a net-debt basis, the ratio would be 1.35x, using net debt of ₹2,052.4 Cr and equity of ₹1,523.1 Cr [6] [5].
Covenant comparison
The latest ICRA credit-facility update lists ₹445.0 Cr of term loans, ₹334.5 Cr of fund-based working-capital facilities and ₹100.0 Cr of NCDs, but does not state lender-specific debt-to-equity covenants or maximum leverage thresholds [1].
ICRA reports the following H1 FY27 ratios, calculated under its own definitions:
- Total outside liabilities / tangible net worth: 2.3x
- Total debt / OPBDIT: 15.6x
- Interest coverage: 0.7x [7]
These are credit-monitoring ratios, not disclosed lender covenant limits, and the 2.3x total-liabilities-to-net-worth measure is not directly comparable with the 1.41x gross debt-to-equity ratio. Therefore, the current leverage can be quantified, but compliance with lender covenants cannot be determined from the latest disclosed facility schedule.
ICRA notes the vulnerability of operating margins to raw material price volatility; how has the company’s EBITDA margin per tonne of Phthalic Anhydride (PA) and Maleic Anhydride (MA) trended over the last eight quarters compared to the industry average, and what is the current hedging policy for key feedstocks like Ortho-Xylene and Benzene?
The requested PA/MA-specific margin comparison cannot be established from the reported data. Thirumalai Chemicals reports consolidated EBITDA, but not EBITDA per tonne separately for Phthalic Anhydride, Maleic Anhydride, or an industry-average benchmark. The available consolidated series shows a volatile but improving margin profile.
Consolidated EBITDA margin trend
The pattern is not a smooth recovery: margins oscillated between negative and positive territory through Q3 FY26, before improving for three consecutive quarters to 8.1% in Q2 FY27. ICRA attributed the H1 FY27 improvement to better PAN–Ortho-Xylene spreads, while warning that sustained profitability remains a monitorable. [1] ICRA’s own H1 FY27 OPBDIT-to-operating-income measure was 6.2%, but that is an aggregate credit-analysis ratio and is not directly comparable with PA/MA EBITDA per tonne. [7]
Comparison with industry average
A valid comparison is not available because:
- PA and MA production volumes, product-level EBITDA, and product-level realisations are not provided.
- The company does not provide a PA-specific or MA-specific EBITDA-per-tonne series in the cited material.
- No industry-average EBITDA-per-tonne benchmark is reported.
- The named peer companies also do not have a confirmed eight-quarter PA/MA EBITDA-per-tonne series in the cited search scope; therefore, their consolidated EBITDA margins should not be used as an industry proxy.
Hedging policy for Ortho-Xylene and Benzene
The current hedging policy could not be confirmed from the cited filings, rating update, financial data, or news. In particular, the material does not establish:
- the proportion of Ortho-Xylene or Benzene purchases hedged;
- whether hedging uses derivatives, forward contracts, inventory matching, or only contractual pass-throughs;
- the hedge tenor, limits, or counterparty policy; or
- whether PA/MA selling prices are reset with a lag against feedstock prices.
The evidence supports exposure to PAN–Ortho-Xylene spread volatility, not a conclusion that the company has a formal financial hedge in place. Accordingly, the key observable protection currently appears to be the spread between product realisations and feedstock costs; the effectiveness and existence of any derivative hedge remain unconfirmed.
_Scope note: this comparison also included Innovassynth Technologies (India) Limited (INOVSYNTH); TGV Sraac (TGVSL); Citurgia Biochemicals Ltd. (CITURGIA); IG Petrochemicals Limited (IGPL), which the answer above does not cover. Ask about any of them for a full side-by-side._
| Quarter | Consolidated EBITDA margin | Analyst read |
|---|---|---|
| Q3 FY25 | -4.5% [8] | Loss-making |
| Q4 FY25 | 4.3% [9] | Recovered into positive territory |
| Q1 FY26 | -5.5% [10] | Sharp reversal |
| Q2 FY26 | 1.1% [11] | Marginally positive |
| Q3 FY26 | -2.7% [12] | Volatility persisted |
| Q4 FY26 | 3.4% [13] | Recovery began |
| Q1 FY27 | 6.6% [14] | Further improvement |
| Q2 FY27 | 8.1% [15] | Highest in the eight-quarter series |
Sources
- [1]ICRA Credit Rating Update for Thirumalai Chemicals Limited — 2026-11-17T19:21:53.483000, p.3
- [2]Current Borrowings
- [3]Thirumalai Chemicals reports Q2 net loss of Rs. 34 crore despite 35% revenue surge — Indianchemicalnews, 2026-11-06T00:00:00
- [4]Total Debt
- [5]Total Equity
- [6]Net Debt
- [7]ICRA Credit Rating Update for Thirumalai Chemicals Limited — 2026-11-17T19:21:53.483000, p.4
- [8]EBITDA Margin
- [9]EBITDA Margin
- [10]EBITDA Margin
- [11]EBITDA Margin
- [12]EBITDA Margin
- [13]EBITDA Margin
- [14]EBITDA Margin
- [15]EBITDA Margin
Keep digging